Xaluritamig

Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.

Dr. William Kevin Kelly discusses AMG 509 (Xaluritamig), a STEAP1-targeted T-cell engager for advanced prostate cancer, highlighting its mechanism, dosing optimization, and efficacy in heavily pretreated patients. He notes manageable cytokine release syndrome and musculoskeletal side effects, with plans for a phase 3 trial comparing Xaluritamig to standard therapies. The drug shows promising results in late-stage prostate cancer, with durable outcomes and potential to change clinical practice, though further research on optimal sequencing and combination strategies is needed.

Amgen presents new oncology data at ESMO Congress 2024, highlighting targeted therapies for colorectal, lung, prostate, and gastric cancers, reflecting their strategy to advance diverse modalities for difficult-to-treat cancers.